Ocumension Therapeutics (FRA:5DG)

Market Cap	675.46M +41.2%
Revenue (ttm)	97.95M +92.7%
Net Income	-19.34M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	96.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	6
Open	0.8000
Previous Close	0.7950
Day's Range	0.7900 - 0.8000
52-Week Range	0.5750 - 1.3500
Beta	n/a
RSI	46.93
Earnings Date	Mar 26, 2026

About Ocumension Therapeutics

Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, age-related mac...

• Industry: Pharmaceutical Preparations
• Founded: 2017
• Employees: 552
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5DG

Financial Performance

In 2025, Ocumension Therapeutics's revenue was 804.35 million, an increase of 92.75% compared to the previous year's 417.31 million. Losses were -158.82 million, -40.80% less than in 2024.

Financial numbers in CNY